Bulletin
Investor Alert

EyePoint Pharmaceuticals Inc.

NAS: EYPT

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
EyePoint Pharmaceuticals Inc.

After Hours

EYPT
/zigman2/quotes/210537129/composite

$

11.11

Change

0.00 0.00%

Volume

Volume 4,749

Aug 12, 2022, 4:01 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/210537129/composite

Previous close

$ 11.09

$ 11.11

Change

+0.02 +0.18%

Day low

Day high

$11.02

$11.44

Open
Open: 11.09

52 week low

52 week high

$7.00

$21.50

Open

Market cap

$378.54M

Average volume

173,414

P/E ratio

N/A

Rev. per Employee

$337,089

EPS

-2.26

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/eypt

MarketWatch News on EYPT

  1. EyePoint Pharmaceuticals downgraded to neutral from buy at B. Riley FBR

    10:32 a.m. April 6, 2020

    - Tomi Kilgore

  2. EyePoint Pharmaceuticals stock price target cut to $4.00 from $5.75 at B. Riley FBR

    9:11 a.m. Sept. 24, 2019

    - Tomi Kilgore

  3. EyePoint Pharma shares jump on FDA approval of Yutiq implant

    7:38 a.m. Oct. 15, 2018

    - Ciara Linnane

  4. EyePoint Pharma shares surge 8% premarket as FDA approves Yutiq for uveitis

    7:31 a.m. Oct. 15, 2018

    - Ciara Linnane

  5. Charting the Market

    4:16 p.m. Jan. 5, 2016

    - Barron's Online

  6. PSivida shares skyrocket after drug meets trial goals

    12:41 p.m. Dec. 22, 2015

    - Emma Court

  7. PSivida's stock soars 41% in active premarket trade after positive trial results

    8:59 a.m. Dec. 22, 2015

    - Tomi Kilgore

  8. PSivida started at outperform with $6 stock price target at FBR & Co.

    8:36 a.m. Oct. 15, 2015

    - Tomi Kilgore

  9. FDA OKs pSivida uveitis drug for Phase III trials

    9:41 a.m. July 19, 2012

    - MarketWatch.com

  10. Monday’s biggest gaining and declining stocks

    6:30 p.m. Dec. 27, 2010

    - Kate Gibson

  11. Alimera, pSivida slammed by FDA move

    3:30 p.m. Dec. 27, 2010

    - Val Brickates Kennedy

  12. Alimera, pSivida crushed by FDA setback

    10:36 a.m. Dec. 27, 2010

    - Val Brickates Kennedy

  13. Alimera, pSivida, Bayer lead drug-stock rally

    1:15 p.m. Aug. 31, 2010

    - Val Brickates Kennedy

  14. Javelin rockets as drug stocks head south

    3:41 p.m. June 29, 2010

    - Val Brickates Kennedy

  15. Forest Labs falls, pSivida rallies

    1:21 p.m. April 8, 2010

    - Val Brickates Kennedy

  16. Stocks in the Spotlight Wednesday

    5:58 p.m. Dec. 23, 2009

    - Barron's Online

  17. Drug stocks sluggish; Achillion, pSivida rally

    2:33 p.m. Dec. 23, 2009

    - Val Brickates Kennedy

Analyst Ratings

/news/nonmarketwatch/company/us/eypt

Other News on EYPT

  1. 10-Q: EYEPOINT PHARMACEUTICALS, INC.

    2:16 p.m. Aug. 5, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  5. Notable earnings before Wednesday's open

    10:48 a.m. Aug. 2, 2022

    - Seeking Alpha

  6. EyePoint reports preliminary Q2 net product revenue $11.3M

    1:46 p.m. July 18, 2022

    - Seeking Alpha

  12. GSK to Boost Vaccine Portfolio With Affinivax Acquisition

    11:26 a.m. May 31, 2022

    - Zacks.com

  13. AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate

    11:46 a.m. May 23, 2022

    - Zacks.com

  15. Horizon (HZNP) Begins Enrollment in Alopecia Areata Study

    11:03 a.m. May 18, 2022

    - Zacks.com

  20. 10-Q: EYEPOINT PHARMACEUTICALS, INC.

    1:45 p.m. May 6, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  21. Loading more headlines...
/news/pressrelease/company/us/eypt

Press Releases on EYPT

  8. EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022

    7:30 a.m. July 11, 2022

    - GlobeNewswire

  11. EyePoint Throws in lot with OcuMension

    9:57 a.m. June 21, 2022

    - Baystreet.ca

  21. Loading more headlines...

Rates »

Mortgage Equity Savings Auto
Link to MarketWatch's Slice.